Novavax has initiated crossover arms in two of its ongoing trials of NVX-CoV2373, the company’s Covid-19 vaccine candidate. Crossover ensures the administration of the vaccine to all participants in the trials taking place in Novavax’s Phase IIb trial in South Africa and Phase III trial in the UK. The company is also planning to include paediatric and adolescent arms in the trial, which is expected to begin in the second quarter.
Tetra Bio-Pharma has announced that the US Food and Drug Administration (FDA) has reviewed the preclinical and clinical development plans of ARDS-003 in the treatment of Covid-19. ARDS-003 is a new therapy developed to treat hyperinflammatory disorders caused by Covid-19. The FDA agreed with the animal toxicology and safety data of ARDS-003 and its safe use in humans for treating severe Covid-19. The company is now working on filing an investigational new drug (IND) application to initiate clinical trials.
Anixa Biosciences will advance into the next stage of development of its antiviral Covid-19 therapy based on proof-of-concept (POC) animal study results. Anixa will collaborate with OntoChem, which specialises in data and bio-IT services, to develop an oral, room temperature-stable, antiviral therapy against the SARS-CoV-2 virus. The partners recently completed POC studies in a Syrian hamster model of the Covid-19 disease.